UMS United Medical Systems International AG

  • WKN: 549365
  • ISIN: DE0005493654
  • Land: Deutschland

Nachricht vom 27.03.2012 | 10:44

UMS AG announces key financial data for 2011 - Management Board and Supervisory Board propose dividend of EUR0.50 per share - Forecast for 2012 is EUR0.60 to EUR0.70 per share


UMS United Medical Systems International AG / Key word(s): Final Results/Dividend

27.03.2012 / 10:44


UMS AG announces key financial data for 2011 - Management Board and Supervisory Board propose dividend of EUR0.50 per share - Forecast for 2012 is EUR0.60 to EUR0.70 per share

Hamburg, 27 March 2012 - UMS United Medical Systems International AG (UMS/ ISIN DE0005493654) today released its key financial data for the 2011 fiscal year. The Company, which offers mobile service solutions for selected fields of medicine, generated earnings per share in the amount of EUR0.47 (2010: EUR0.61). This lies within the adjusted bandwidth of EUR0.45 to EUR0.55 per share that was announced last August.

As previously announced, UMS AG expects to maintain its dividend policy for 2011. Management Board and the Supervisory Board therefore plan to propose to the shareholders' meeting on May 31, 2012 to again distribute a dividend of EUR0.50 per share as in the previous year. This dividend will be paid from the company's capital contributions account for tax purposes.

According to IFRS figures, the UMS Group's revenues amounted to EUR38.3 million in fiscal 2011, as opposed to EUR38.9 million in the previous year. However, if exchange rate effects are ignored, revenues grew by EUR1.5 million, or 4%.

Group EBIT for 2011 amounted to EUR11.6 million, as compared to EUR12.8 million in the previous year. Consolidated net income for 2011 amounted to EUR9.2 million, of which EUR2.3 million was attributable to the Group's shareholders (2010: EUR3.1 million).

Jorgen Madsen, the CEO of UMS AG, explains: 'Particularly in the first half of 2011, two factors temporarily had an adverse effect on our earnings: the acquisition of a competitor and the start-up phase of additional equipment capacities in the radiology sector. In the meantime, we have almost fully booked the additional capacities and successfully completed the integration of the acquired competitor. This makes us confident that we will see revenue and earnings growth in the current fiscal year.'

UMS expects revenue growth to continue in fiscal year 2012 and thus expects consolidated revenues between EUR41 million and EUR43 million. UMS expects earnings per share to increase significantly in 2012, to between EUR0.60 to EUR0.70.

UMS will publish the complete audited financial statements for fiscal year 2011 on April 3, 2012.

About UMS AG

UMS International AG is a provider of innovative healthcare delivery concepts in the growth segment of high-tech medicine. UMS pioneered the mobile deployment of high-class medical systems and markets a comprehensive range of full-service solutions for hospitals and specialist physicians. The forward-looking concepts include complete services for the customer, covering everything from system management to the provision of trained application specialists. The UMS Group currently has over 220 employees worldwide and serves over 650 customers.

Contact:

Christian Möller, Tel: (040) 500 177-00, Fax: (040) 500 177-77, E-Mail: investor@umsag.com



End of Corporate News


27.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de



162419  27.03.2012

Anleihe im Fokus

Die DF-Anleihe 7,875%

Mit der DF Forfait AG vom wachsenden Welthandel profitieren

- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

HELMA Eigenheimbau AG: Kaufen

Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.

News im Fokus

Fresenius Medical Care AG & Co. KGaA: Bekanntmachung nach Art. 4 Abs. 2 der Verordnung (EG) Nr. 2273/2003

17. Mai 2013, 17:35

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG

17. Mai 2013